Summary effects of LABA/LAMA combinations versus comparators on adverse events
| Mortality FE HR (95% CrI) | Total SAEs FE HR (95% CrI) | Cardiac SAEs RE HR (95% CrI) | Dropouts due to AE RE HR (95% CrI) | |
|---|---|---|---|---|
| No. of studies | 15 | 20 | 16 | 16 |
| No. of patients | 24 041 | 27 172 | 25 913 | 23 529 |
| vs placebo | 1.95 (0.73, 7.71) | 1.10 (0.89, 1.38) | 1.65 (0.81, 3.35) | 0.95 (0.71, 1.28) |
| vs LABA | 0.99 (0.61, 1.66) | 0.96 (0.84, 1.10) | 0.82 (0.46, 1.35) | 0.92 (0.72, 1.19) |
| vs LAMA | 0.87 (0.64, 1.16) | 1.04 (0.95, 1.14) | 0.87 (0.59, 1.27) | 1.03 (0.84, 1.26) |
AE, adverse event; CrI, credible interval; FE, fixed-effects; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; RE, random-effects; SAE, serious adverse event.